Skip to main content
Fig. 3 | Cancer Nanotechnology

Fig. 3

From: ADAMTS9-AS1 inhibits tumor growth and drug resistance in clear cell renal cell carcinoma via recruiting HuR to enhance ADAMTS9 mRNA stability

Fig. 3

ADAMTS9-AS1 inhibits ccRCC cell viability and sensitivity to 5-aza-dC in vitro. A. ADAMTS9-AS1 overexpression and KD efficiency was confirmed by qRT-PCR in A498 cells. B-C. Cell growth was determined by CCK-8 (left) and colony formation (right) assays following ADAMTS9-AS1 overexpression (B) and KD (C) in A498 cells. D Cell viability of A498 cells were detected by CCK-8 assay following ADAMTS9-AS1 overexpression (left) or ADAMTS9-AS1 knockdown (right) and treatment with a concentration gradient of 5-aza- dC. E The apoptosis ratio was detected by FACS assay following ADAMTS9-AS1 overexpression (left) or ADAMTS9-AS1 knockdown (right) in A498 cells with or without 5-aza-dC treatment. The data derived from three independent experiments are presented as mean ± SEM in the bar graphs A–E. Controls were normalized to 1 (A–D). *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us